Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956736 | 1.00 | POLB (0.37) | POLBAPEX1HPGDSMN1; SMN2TSHR | |
| SCHEMBL30905967 | 0.88 | KDM1A (0.35) | POLBAPEX1HPGDSMN1; SMN2TSHR | |
| SCHEMBL3584961 | 0.88 | ALDH1A1 (0.34) | TSHRMAPT | |
| SCHEMBL30241530 | 0.84 | CYP3A4 (0.35) | SMN1; SMN2CYP3A4NPC1RAB9A | |
| SCHEMBL15757290 | 0.84 | SMN1; SMN2 (0.32) | POLBAPEX1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL15757566 | 0.84 | CYP3A4 (0.35) | SMN1; SMN2CYP3A4NPC1RAB9A | |
| SCHEMBL29950958 | 0.84 | SMN1; SMN2 (0.32) | POLBAPEX1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL25170326 | 0.83 | KDM1A (0.35) | POLBAPEX1HPGDSMN1; SMN2TSHR | |
| SCHEMBL31332518 | 0.81 | TTR (0.36) | HPGDSMN1; SMN2TSHRTTRCYP3A4 | |
| SCHEMBL6082901 | 0.79 | ENPP2 (0.39) | HPGDSMN1; SMN2MAPTLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2022-04-07 | — | — | US | disclosed |
| EP-3810598-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019244049-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106296-A1 | CYANOTRIAZOLE COMPOUNDS AND USES THEREOF | CBR3, HCRTR1, CYP4F11 | POLB 2408/4885APEX1 1691/4885HPGD 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.